Skip to content
Peptigraph home

REDEFINE 1: CagriSema Phase 3 trial (NCT05567796)

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

Registry record checked

At a glance

Phase
Phase 3
Status
Active, not recruiting
Enrolment
3,400
estimated
Start
1 Nov 2022 (actual)
Primary completion
30 Oct 2024 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT05567796 study arms
ArmTypeInterventionsDescription
CagrisemaExperimentalDrug: Cagrilintide; Drug: SemaglutideParticipants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.
CagrilintideActive comparatorDrug: Cagrilintide; Drug: Placebo semaglutideParticipants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.
SemaglutideActive comparatorDrug: Semaglutide; Drug: Placebo cagrilintideParticipants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.
Placebo s.c.Placebo comparatorDrug: Placebo cagrilintide; Drug: Placebo semaglutideParticipants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.
Endpoints

Primary endpoint

NCT05567796 primary outcomes
MeasureTime frame
CagriSema versus placebo: Relative change in body weightFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reductionFrom baseline (week 0) to end of treatment (week 68)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05567796 secondary outcomes
MeasureTime frame
CagriSema versus placebo: Achievement of >= 20% weight reductionFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of >= 25% weight reductionFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of >= 30% weight reductionFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weightFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Relative change in body weightFrom baseline (week 0) to week 8
CagriSema versus placebo: Relative change in body weightFrom baseline (week 0) to week 20
CagriSema versus placebo: Change in waist circumferenceFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in systolic blood pressure (SBP)From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function ScoreFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning ScoreFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo, semaglutide and cagrilintide: Change in body weightFrom baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI)From baseline (week 0) to end of treatment (week 68)
Eligibility

Who could enrol

Sex
All
Minimum age
[pending]
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Weight results from the REDEFINE 1 paper

REDEFINE 1 randomised participants 21:3:3:7 to the combination, semaglutide alone, cagrilintide alone or placebo, each at 2.4 mg, plus lifestyle interventions.[2]

At week 68 the mean weight change was -20.4% with the combination against -3.0% with placebo, a difference of -17.3 percentage points.[2]

Gastrointestinal events affected 79.6% of the combination group and 39.9% of the placebo group.[2]

Blood pressure findings from a REDEFINE 1 analysis

Systolic pressure fell by 10.9 mm Hg with CagriSema against 2.8 mm Hg with placebo, and diastolic by 5.4 against 1.7 mm Hg.[3]

Blood pressure targets were reached at week 68 by 63.0% on CagriSema and 32.0% on placebo.[3]

Among people on antihypertensive medication, 39.6% in the CagriSema group reduced or stopped it, against 18.8% on placebo.[3]

Anthropometric targets in a post hoc analysis

Both a BMI under 27 and a waist-to-height ratio under 0.53 were reached by 30.3% on CagriSema, 19.1% on semaglutide, 9.0% on cagrilintide and 3.3% on placebo.[4]

Sources

  1. 1Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
  3. 3CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
  4. 4Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2026PMID 42503495Accessed 2 Oct 2026

Found an error? Report a correction.